A Phase II Study of 131I-rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Sponsor
Korea Cancer Center Hospital
Study ID
NCT01676558
Phase
PHASE2
Status
Unknown

Conditions

  • Relapsed or Refractory Diffuse Large B Cell Lymphoma

Eligibility Criteria

Sex
ALL
Age
20 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma in Korea. Although there is standard therapy, which is called 'R-CHOP', many obstacles to use aggressive cytotoxic chemotherapeutic agents such as old age, poor performance status, refractoriness, and relapsed disease still remains. So we investigate the efficacy of radioimmunotherapy using 131I-rituximab in refractory or relapsed patients with DLBCL.

Key Dates

Start date
Jun 30, 2012
Status verified
Aug 2012
Primary completion
Jun 30, 2016
Completion
Jun 30, 2017

Study Design

Enrollment
24 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 131I-rituximab
    131I-rituximab treatment interval at least 4 weeks up to maximum 6 cycles

Primary Outcome Measure

overall response rate [ Time Frame: up to 5 years ]

Central Contacts